Pisa

• Phase 2 Study of LAD191 in Adults With Hidradenitis Suppurativa Recruiting
  2025-521293-34-00 4 2025-12-09 Moderate-to-severe hidradenitis suppurativa
• Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC. Recruiting
  2024-516906-47-00 10 2025-11-28 Locally Advanced or Metastatic Urothelial Carcinoma
• AMG 410 Alone and in Combination with other agents in Participants with KRAS Altered Advanced or Metastatic Solid Tumors Recruiting
  2025-521707-48-00 1 2025-11-26 KRAS Altered Advanced or Metastatic Solid Tumors
• Upfront trastuzumab-deruxtecan plus capecitabine and bevacizumab for patients with HER2 positive metastatic colorectal cancer: the CHIMERA t … Recruiting
  2024-519479-24-00 4 2025-11-21 metastatic colorectal cancer
• A multicenter, prospective, randomized, double blind, placebo controlled, adaptive design study performed to evaluate the efficacy and the s … Recruiting
  2024-519623-23-00 5 2025-10-20 Venous leg ulcer
• A Phase 3 Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder Recruiting
  2024-520259-26-00 5 2025-09-25 Mania or Mania with Mixed Features in Bipolar-I Disorder
• Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obe … Recruiting
  2024-520209-38-00 5 2025-09-19 Obesity or Overweight
• COLCOT-T2D Recruiting
  2024-516646-19-00 5 2025-08-15 Type 2 diabetic patients with no prior cardiovascular (CV) events
• BOLD-100 in Combination with FOLFOX for the Treatment of Advanced Solid Tumours Recruiting
  2024-517500-11-00 7 2025-07-15 Colorectal Cancer
• AFFIRM: A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Pri … Recruiting
  2024-516525-31-01 5 2025-07-14 Primary Biliary Cholangitis
• A Phase 3, Single-Arm, Multiple-Dose, Pharmacokinetic Comparability Trial Between TAK-881 and HYQVIA in Adults With Chronic Inflammatory Dem … Recruiting
  2024-517450-95-00 5 2025-06-23 Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
• A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with … Recruiting
  2024-513965-38-01 5 2025-06-16 Sjögren's Disease
• Long-term safety and efficacy study of riliprubart in participants with CIDP Recruiting
  2024-517032-22-00 5 2025-06-10 Immune system diseases.
• Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Pancreatic Cancer (Substudy PDAC) Recruiting
  2024-517819-74-00 9 2025-06-02 Pancreatic Ductal Adenocarcinoma
• A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab a … Recruiting
  2023-505172-29-00 4 2025-04-24 Resectable Non-small Cell Lung Cancer
• A Phase 2 Study of AMG 193 in Subjects With MTAP-deleted Advanced NSCLC Recruiting
  2024-514459-14-00 4 2025-04-22 Non-Small Cell Lung Cancer
• A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-022) Recruiting
  2023-508015-23-00 5 2025-04-11 Ovarian cancer recurrent
• A dose ranging study to investigate efficacy and safety of subcutaneous TOUR006 compared with placebo in participants 18 to 80 years of age … Recruiting
  2024-514801-69-00 4 2025-04-02 Thyroid Eye Disease
• A study of the efficacy and safety of Belimumab in adults with interstitial lung disease associated with connective tissue disease. Recruiting
  2024-513018-36-00 5 2025-03-06 Lung Diseases, Interstitial
• A clinical trial to learn about the effects of VHB937 in people with amyotrophic lateral sclerosis (ALS) Recruiting
  2024-512536-29-00 4 2025-02-28 Amyotrophic Lateral Sclerosis (ALS)
• A trial to investigate teprotumumab mg/ml subcutaneous administration compared with placebo in male and female adult participants with moder … Recruiting
  2024-515702-63-00 5 2025-02-20 Moderate-to-Severe Active Thyroid Eye Disease
• Selective Treatment of Oral Povorcitinib in Prurigo Nodularis Study 1 (STOP-PN1) Recruiting
  2024-511879-16-00 5 2024-12-12 Prurigo Nodularis
• Letrozole for Estrogen/Progesterone Receptor positive low-grade serous Epithelial ovarian cancer. A randomized phase III trial. LEPRE Trial Recruiting
  2024-516874-31-00 5 2024-12-10 Patients with a low-grade serous epithelial carcinoma of the ovary (LG
• Steroid withdrawal in SLE Recruiting
  2024-518580-35-00 6 2024-11-20 Systemic Lupus Erythematosus

Showing 73–96 of 550 trials